ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MNKD vs JANX // REVENUE GROWTH (YOY)

MannKind Corporation (NASDAQ) VS. Janux Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MNKD 5 — JANX 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNKD VS. JANX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MNKD JANX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 92.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 54.50% -13.80% +68.30 MNKD /roic <GO>
EV/EBITDA & P/E Valuation 24.6x — — TIE /valuation <GO>
Free Cash Flow Yield 1.22% -7.64% +8.86 MNKD /fcf-yield <GO>
Operating Margin 11.10% — — TIE /operating-margins <GO>
Net Profit Margin 1.70% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE 22.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 MNKD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.6 55.0 +0.60 MNKD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.13B $1.09B $35.3M MNKD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MNKD REV JANX REV MNKD GROSS % JANX GROSS % MNKD FCF JANX FCF
FY 2025 $349.0M $0 92.3% — $13.7M -$83.3M
FY 2024 $285.5M $0 93.9% — $32.8M -$44.2M
FY 2023 $199.0M $0 — — $34.1M -$50.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MNKD // BETA —
JANX // BETA —